Bio-Techne price target lowered to $87 from $92 at Stephens

Stephens analyst Jacob Johnson lowered the firm’s price target on Bio-Techne to $87 from $92 and keeps an Overweight rating on the shares after the company reported a Q2 miss that included both segments falling short of expectations. While near-term and long-term growth may remain debated, the firm thinks the current valuation is “reasonable” and notes that the company said it expects no further deceleration in growth, while margins should improve sequentially.